Cell No. : Cell Name
RCB1990 : KUSA-H1
update : 2024/05/30
|
| Comment | Mouse bone marrow-derived stromal cells. |
| Comment from the depositor | |
| Terms and conditions | There is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC. |
| Remarks | |
| Order Form |
Order Form(C-0005.pdf)
MTA(C-0007.pdf)
MTA(C-0007p.pdf)
|
|
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
|
|
|
Basic information
|
Depositor |
Umezawa, Akihiro
|
| Originator |
Umezawa, Akihiro
|
| Year of deposit |
2005
|
| Animal |
_mouse
< Mammals
|
| Strain name |
C3H/He
|
| Gender |
Female
|
| Tissue |
bone marrow
|
| Classification |
normal
|
|
Lifespan |
infinite
|
| Morphology |
fibroblast-like
|
| Cellosaurus(Expasy) |
CVCL_5222
|
|
| |
deposit info |
lot info |
|
Medium |
Medium List |
|
Culture type |
|
Adherent cells
|
| Culture medium |
|
POWEREDBY10
|
| Antibiotics |
|
Free
|
|
Passage method |
|
0.25% Trypsin
|
Culture information
|
Passage cell No |
|
2 x 10 5 cells/100 mm dish
|
| SC frequency |
|
Subculture : 2 times/week
|
| Temperature |
|
37
℃
|
| CO2 concentration |
|
5
%
|
| Freeze medium |
|
Medium + 10% DMSO
|
| Freezing method |
|
Slow freezing
|
| Mycoplasma/Acholeplasma |
|
(-)
|
| SSLP(mouse) |
|
OK
|
| Isozyme |
|
LD, NP
|
| Reference information |
Reference |
1
|
| User's Publication |
6
|
| User's Publication |
|
4352
Ding L, Zhang W, Yang L, Pelicano H, Zhou K, Yin R, Huang R, Zeng J.
Targeting the autophagy in bone marrow stromal cells overcomes resistance to vorinostat in chronic lymphocytic leukemia.
Onco Targets Ther
2018
11:5151-5170
PubMed ID: 30210236
DOI: 10.2147/OTT.S170392
|
|
15661
Fiorcari S, Brown WS, McIntyre BW, Estrov Z, Maffei R, O'Brien S, Sivina M, Hoellenriegel J, Wierda WG, Keating MJ, Ding W, Kay NE, Lannutti BJ, Marasca R, Burger JA.
The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells
PLoS One
2013
8(12):e83830
PubMed ID: 24376763
DOI: 10.1371/journal.pone.0083830
|
|
15649
Sivina M, Hartmann E, Vasyutina E, Boucas JM, Breuer A, Keating MJ, Wierda WG, Rosenwald A, Herling M, Burger JA.
Stromal cells modulate TCL1 expression, interacting AP-1 components and TCL1-targeting micro-RNAs in chronic lymphocytic leukemia
Leukemia
2012
26(8):1812-20
PubMed ID: 22460735
DOI: 10.1038/leu.2012.63
|
|
7732
Hoellenriegel J, Meadows SA, Sivina M, Wierda WG, Kantarjian H, Keating MJ, Giese N, O'Brien S, Yu A, Miller LL, Lannutti BJ, Burger JA.
The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia.
Blood
2011
118:3603-12
PubMed ID: 21803855
DOI: 10.1182/blood-2011-05-352492
|
|
15652
Chen R, Guo L, Chen Y, Jiang Y, Wierda WG, Plunkett W.
Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia
Blood
2011
117(1):156-64
PubMed ID: 20971952
DOI: 10.1182/blood-2010-01-262808
|
|
8493
Kurtova AV, Balakrishnan K, Chen R, Ding W, Schnabl S, Quiroga MP, Sivina M, Wierda WG, Estrov Z, Keating MJ, Shehata M, Jager U, Gandhi V, Kay NE, Plunkett W, Burger JA.
Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance.
Blood
2009
114:4441-50
PubMed ID: 19762485
DOI: 10.1182/blood-2009-07-233718
|
Back
Top
CELL BANK Website